7.83
前日終値:
$7.82
開ける:
$7.72
24時間の取引高:
1.51M
Relative Volume:
0.88
時価総額:
$2.45B
収益:
$2.68B
当期純損益:
$-184.45M
株価収益率:
-11.51
EPS:
-0.6805
ネットキャッシュフロー:
$229.23M
1週間 パフォーマンス:
-2.85%
1か月 パフォーマンス:
-4.63%
6か月 パフォーマンス:
-5.21%
1年 パフォーマンス:
+9.05%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
AMRX
Amneal Pharmaceuticals Inc
|
7.83 | 2.45B | 2.68B | -184.45M | 229.23M | -0.6805 |
![]()
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-06-06 | 開始されました | Goldman | Buy |
2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
2021-03-08 | アップグレード | Goldman | Sell → Buy |
2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
2020-07-27 | 開始されました | Goldman | Sell |
2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
2019-06-11 | 開始されました | Barclays | Equal Weight |
2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
2019-03-20 | 開始されました | SunTrust | Buy |
2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2018-07-23 | 開始されました | Morgan Stanley | Overweight |
2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal Pharmaceuticals Secures $2.1 Billion in Loans - TipRanks
How does Amneal Pharmaceuticals Inc. compare to its industry peersBest Dividend Report From AI Tools - jammulinksnews.com
What makes Amneal Pharmaceuticals Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com
What is Amneal Pharmaceuticals Inc. company’s growth strategyBreakout Stocks Strategy With Low Risk - jammulinksnews.com
Truist Financial Maintains a Buy on Amneal Pharmaceuticals (AMRX) With an $8 PT - Insider Monkey
How strong is Amneal Pharmaceuticals Inc. company’s balance sheetEntry Signal Growth Plan For Every Investor - jammulinksnews.com
Amneal Launches GLP-1 Agonist Exenatide Injection - Specialty Pharmacy Continuum
Teva Drops Inhaler Patent Infringement Lawsuit Against Amneal - Bloomberg Law News
Is Amneal Pharmaceuticals Inc. a candidate for recovery playReversal Alert Based on RSI Indicator Confirmed - metal.it
Amneal Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayStock Market Watch With Alerts Shows Unusual Activity - metal.it
Teva, Amneal End Case Over Listing Inhaler IP In Orange Book - Law360
Why Amneal Pharmaceuticals Inc. stock attracts strong analyst attentionAI Driven Stock Trend Forecast Shows Momentum Shift - metal.it
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a Bet - Zacks Investment Research
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Q1 Earnings Highlights: Amneal, ANI, Amphastar, and ViatrisNews and Statistics - IndexBox
Q1 Earnings Highs And Lows: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Published on: 2025-07-29 09:45:24 - metal.it
Published on: 2025-07-28 20:38:28 - metal.it
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What are the technical indicators suggesting about Amneal Pharmaceuticals Inc.Capitalize on momentum stocks early - jammulinksnews.com
Is Amneal Pharmaceuticals Inc. a growth stock or a value stockAchieve consistent profits with smart trading - jammulinksnews.com
What institutional investors are buying Amneal Pharmaceuticals Inc. stockExceptional earning trajectories - jammulinksnews.com
How does Amneal Pharmaceuticals Inc. generate profit in a changing economyUnlock high-yield investment opportunities - jammulinksnews.com
How many analysts rate Amneal Pharmaceuticals Inc. as a “Buy”Achieve rapid financial growth with expert picks - jammulinksnews.com
How Amneal Pharmaceuticals Inc. stock performs during market volatilityFree Stock Selection with 300% Return - metal.it
Truist Financial Sticks to Its Buy Rating for Amneal Pharmaceuticals (AMRX) - The Globe and Mail
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastMassive portfolio appreciation - PrintWeekIndia
What drives Amneal Pharmaceuticals Inc. stock priceFree Investment Community - PrintWeekIndia
Amneal Pharmaceuticals Prices $600M Senior Notes Offering - MSN
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
Is Amneal Pharmaceuticals Inc. a good long term investmentPowerful profit generation - PrintWeekIndia
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan - Investing.com Nigeria
What analysts say about Amneal Pharmaceuticals Inc. stockFree Investment Community - Autocar Professional
Amneal Pharmaceuticals prices $600 million in senior secured notes, increases term loan By Investing.com - Investing.com South Africa
Why Investors Shouldn't Be Surprised By Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Low P/S - simplywall.st
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results - The Globe and Mail
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):